Merck's New Drug Significantly Lowers Cholesterol Levels
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 30 2026
0mins
Should l Buy MRK?
Source: seekingalpha
- Clinical Trial Results: Merck's oral PCSK9 inhibitor enlicitide decanoate demonstrated significant efficacy in phase 3 trials, achieving a 64.6% reduction in low-density lipoprotein cholesterol (LDL-C) over eight weeks when added to statin therapy, indicating its potential in cardiovascular disease treatment.
- Comparative Study Advantages: In head-to-head comparisons, enlicitide reduced LDL-C by 56.7% compared to bempedoic acid, 36% compared to ezetimibe, and 28.1% compared to the combination of bempedoic acid and ezetimibe, showcasing its superiority across various treatment regimens.
- Secondary Endpoint Achievement: The study also met secondary endpoints, demonstrating reductions in apolipoprotein B and non-high-density lipoprotein cholesterol, further validating its effectiveness in improving lipid profiles.
- FDA Priority Certification: Enlicitide received an FDA Commissioner National Priority Voucher in December, highlighting its competitive edge in the market, especially given the current landscape dominated by injectable PCSK9 inhibitors, which may drive patient preference towards its oral formulation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 109.180
Low
95.00
Averages
119.53
High
139.00
Current: 109.180
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck Reports Strong Q1 2026 Earnings, Exceeds Expectations
- Significant Revenue Growth: Merck's Q1 2026 revenue reached $16.29 billion, reflecting a 4.9% year-on-year increase that surpassed analyst expectations of $15.82 billion, indicating robust performance in oncology and animal health sectors.
- Improved Adjusted EPS: The company reported an adjusted loss of $1.28 per share, which was 13.2% better than the consensus estimate of $1.47, showcasing management's confidence in new product launches and rising market demand.
- New Product Launches Drive Growth: Merck introduced IDVYNSO for HIV and NUMELVI for canine allergic dermatitis, signaling ongoing efforts to expand its product portfolio and market reach, which are expected to fuel future revenue growth.
- Strategic Investments and Restructuring: Merck plans to increase commercial and R&D spending to support new product launches while reorganizing its commercial operations to enhance execution, with expectations that these initiatives will create long-term value over the next decade.
See More
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Analysis of URTH ETF's 52-Week Highs and Lows
- 52-Week Price Range: URTH ETF's low point is $155.05 and high point is $197.88, with the last trade matching the high at $197.88, indicating significant price stability and investor confidence over the past year.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper insights into market trends, aiding in identifying potential buy or sell opportunities to optimize investment strategies.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, allowing for greater flexibility and adaptability to market changes, thus meeting liquidity needs for investors.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF units highlights notable inflows or outflows, with inflows necessitating the purchase of underlying assets and outflows potentially leading to their sale, directly impacting the ETF's component holdings.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
Moderna Surpasses Q1 Revenue Estimates Driven by International Vaccine Sales
- International Revenue Surge: Moderna's Q1 international revenue reached $311 million, significantly outpacing the $78 million from U.S. markets, demonstrating strong sales driven by partnerships in the UK, Canada, and Australia, thereby balancing its revenue structure between international and domestic markets.
- Vaccine Policy Impact: Major changes in U.S. vaccine policy have led to reduced vaccine usage, with Moderna's CFO expressing hope for a more stable market moving forward, anticipating a recovery in the U.S. COVID market by 2026, which will influence the company's long-term strategy.
- Strong Financial Performance: Moderna reported Q1 revenue of $389 million, an increase of $281 million year-over-year, exceeding analysts' expectations of $228 million, indicating robust performance in the vaccine market and a recovery in demand.
- New Product Development: The company is expanding its product line with plans for an mRNA flu vaccine and developing a personalized cancer vaccine in partnership with Merck, as well as treatments for rare metabolic disorders, showcasing its strategic shift in the post-pandemic era.
See More
Merck & Co., Inc. Q1 2026 Earnings Call Insights
- Revenue Growth: Merck reported Q1 2026 revenue of $16.3 billion, reflecting a 5% year-over-year increase, driven by strong performance in oncology and animal health, indicating sustained growth potential bolstered by new product contributions.
- Acquisition Plans: The planned acquisition of Terns Pharmaceuticals is expected to add TERN-701, which has multibillion-dollar commercial potential, positioning it as a significant growth driver for the next decade and enhancing Merck's competitive edge in the biopharmaceutical sector.
- Financial Outlook: Merck raised its 2026 revenue guidance to between $65.8 billion and $67 billion, with EPS expected between $5.04 and $5.16, demonstrating confidence in future performance despite a projected one-time R&D charge of $5.8 billion from the acquisition.
- Product Sales Dynamics: Sales of the KEYTRUDA family increased by 8% to $8 billion, while GARDASIL sales fell by 22% to $1.1 billion, reflecting market demand fluctuations, particularly a decline in vaccine demand in China and Japan.
See More
Merck Reports Strong Q1 2026 Earnings, Exceeds Expectations
- Significant Revenue Growth: Merck's Q1 2026 revenue reached $16.29 billion, reflecting a 4.9% year-on-year increase that surpassed analyst expectations of $15.82 billion, indicating robust performance in oncology and animal health sectors.
- Improved Adjusted EPS: The company reported an adjusted loss of $1.28 per share, which was 13.2% better than the consensus estimate of $1.47, showcasing management's confidence in new product launches and rising market demand.
- New Product Launches Drive Growth: Merck introduced IDVYNSO for HIV and NUMELVI for canine allergic dermatitis, signaling ongoing efforts to expand its product portfolio and market reach, which are expected to fuel future revenue growth.
- Strategic Investments and Restructuring: Merck plans to increase commercial and R&D spending to support new product launches while reorganizing its commercial operations to enhance execution, with expectations that these initiatives will create long-term value over the next decade.
See More
Knoa Pharma Establishes New Board to Enhance Public Health Initiatives
- Company Formation Background: Knoa Pharma LLC begins operations independently on May 1, 2026, aiming to ensure safe access to critical medicines while addressing the opioid crisis and enhancing public health, marking a new chapter following Purdue Pharma's bankruptcy.
- Innovative Governance Structure: Knoa Pharma is 100% owned by the newly established non-profit Knoa Foundation, which has created two independent boards to ensure strong oversight and accountability in drug production and distribution, thereby enhancing public trust.
- Commitment to Public Health: Knoa Pharma will manufacture existing medicines, including opioid analgesics, safely and responsibly without promoting opioid products, operating under a strict injunction to minimize the risk of drug diversion and support the U.S. response to the opioid crisis.
- Leadership Team Composition: The new board comprises leaders with extensive experience in public health, drug policy, and corporate governance, ensuring the company meets critical patient needs while promoting sustainable and transparent operations that enhance social responsibility.
See More
Analysis of URTH ETF's 52-Week Highs and Lows
- 52-Week Price Range: URTH ETF's low point is $155.05 and high point is $197.88, with the last trade matching the high at $197.88, indicating significant price stability and investor confidence over the past year.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides investors with deeper insights into market trends, aiding in identifying potential buy or sell opportunities to optimize investment strategies.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, allowing for greater flexibility and adaptability to market changes, thus meeting liquidity needs for investors.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF units highlights notable inflows or outflows, with inflows necessitating the purchase of underlying assets and outflows potentially leading to their sale, directly impacting the ETF's component holdings.
See More
Biotech Dealmaking Accelerates Ahead of Patent Cliffs
- Surge in M&A Activity: Biotech M&A deal value reached $84 billion in Q1 2026, a staggering 89.4% increase from $44.4 billion a year earlier, indicating a robust market recovery, with projections suggesting total annual deal value could exceed $250 billion, ranking second only to 2019.
- Patent Cliffs Catalyst: Pharmaceutical companies are accelerating M&A due to impending patent cliffs, with over $300 billion in revenue facing loss of exclusivity in the next five years, particularly with Merck's Keytruda losing exclusivity in 2028, adding to market uncertainty.
- Strong Cash Reserves Fuel Acquisitions: Eli Lilly, for instance, ended 2025 with over $7.27 billion in cash and equivalents, having spent over $35 billion on acquisitions in 2023, demonstrating that strong financial positions make M&A decisions more justifiable at the board level.
- Mid-Sized Deals Dominate: Recent CEO transitions at GSK and Novo Nordisk have led to more aggressive M&A strategies, with analysts noting that the global revenue exposed to patent expirations over the next seven years is 2.5 times higher than in the last 16 years, further driving the activity in mid-sized deals.
See More
Moderna Surpasses Q1 Revenue Estimates Driven by International Vaccine Sales
- International Revenue Surge: Moderna's Q1 international revenue reached $311 million, significantly outpacing the $78 million from U.S. markets, demonstrating strong sales driven by partnerships in the UK, Canada, and Australia, thereby balancing its revenue structure between international and domestic markets.
- Vaccine Policy Impact: Major changes in U.S. vaccine policy have led to reduced vaccine usage, with Moderna's CFO expressing hope for a more stable market moving forward, anticipating a recovery in the U.S. COVID market by 2026, which will influence the company's long-term strategy.
- Strong Financial Performance: Moderna reported Q1 revenue of $389 million, an increase of $281 million year-over-year, exceeding analysts' expectations of $228 million, indicating robust performance in the vaccine market and a recovery in demand.
- New Product Development: The company is expanding its product line with plans for an mRNA flu vaccine and developing a personalized cancer vaccine in partnership with Merck, as well as treatments for rare metabolic disorders, showcasing its strategic shift in the post-pandemic era.
See More
Merck & Co., Inc. Q1 2026 Earnings Call Insights
- Revenue Growth: Merck reported Q1 2026 revenue of $16.3 billion, reflecting a 5% year-over-year increase, driven by strong performance in oncology and animal health, indicating sustained growth potential bolstered by new product contributions.
- Acquisition Plans: The planned acquisition of Terns Pharmaceuticals is expected to add TERN-701, which has multibillion-dollar commercial potential, positioning it as a significant growth driver for the next decade and enhancing Merck's competitive edge in the biopharmaceutical sector.
- Financial Outlook: Merck raised its 2026 revenue guidance to between $65.8 billion and $67 billion, with EPS expected between $5.04 and $5.16, demonstrating confidence in future performance despite a projected one-time R&D charge of $5.8 billion from the acquisition.
- Product Sales Dynamics: Sales of the KEYTRUDA family increased by 8% to $8 billion, while GARDASIL sales fell by 22% to $1.1 billion, reflecting market demand fluctuations, particularly a decline in vaccine demand in China and Japan.
See More
